Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lamotrigine hydrate 是口服有效的抗惊厥剂或抗癫痫剂 ,通过选择性地阻断电压门控Na+通道,稳定突触前神经元膜并抑制谷氨酸释放。Lamotrigine hydrate 可用于研究癫痫、局灶性癫痫等神经性疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
Lamotrigine hydrate 的其他形式现货产品:
产品描述 | Lamotrigine hydrate is an effective oral active anticonvulsant or antiepileptic agent that selectively blocks voltage-gated Na + channels, stabilizes presynaptic neuronal membranes and inhibits glutamate release. Lamotrigine hydrate can be used in epilepsy, focal seizure, et al [1] [2]. |
体外活性 | Lamotrigine hydrate inhibits Veratrine evoked release of glutamate and aspartate with ED 50 values of 21 μM for both amino acids, but Lamotrigine hydrate is less potent in the inhibition of GABA release (ED 50 =44 μM. At concentrations up to 300 μM, LTG has no effect on patassium-evoked amino acid [1]. Lamotrigine hydrate is some five times less potent in the inhibition of Veratrine-evoked [ 3 H]acetylcholine release (ED 50 =100 μM) than in glutamate or aspartate release [1]. |
体内活性 | Lamotrigine hydrate (IP, 30 min before pentylenetetrazol; 10 mg/kg, 15 mg/kg or 20 mg/kg) decreases the seizure intensity at the higher doses, it increases the latency to the first pentylenetetrazol-induced seizure in all studied doses compared with the controls [2]. |
分子量 | 274.11 |
分子式 | C9H9Cl2N5O |
CAS No. | 375347-20-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lamotrigine hydrate 375347-20-9 Inhibitor inhibitor inhibit